| Literature DB >> 30108871 |
Robin A Fairhurst1, Thomas Knoepfel1, Catherine Leblanc1, Nicole Buschmann1, Christoph Gaul1, Jutta Blank1, Inga Galuba1, Jörg Trappe1, Chao Zou1, Johannes Voshol1, Christine Genick1, Peggy Brunet-Lefeuvre1, Francis Bitsch1, Diana Graus-Porta1, Pascal Furet1.
Abstract
A diverse range of selective FGFR4 inhibitor hit series were identified using unbiased screening approaches and by the modification of known kinase inhibitor scaffolds. In each case the origin of the selectivity was consistent with an interaction with a poorly conserved cysteine residue within the middle-hinge region of the kinase domain of FGFR4, at position 552. Targeting this region identified a non-covalent diaminopyrimidine series differentiating by size, an irreversible-covalent inhibitor in which Cys552 undergoes an SNAr reaction with a 2-chloropyridine, and a reversible-covalent inhibitor series in which Cys552 forms a hemithioacetal adduct with a 2-formyl naphthalene. In addition, the introduction of an acrylamide into a known FGFR scaffold identified a pan-FGFR inhibitor which reacted with both Cys552 and a second poorly conserved cysteine on the P-loop of FGFR4 at position 477 which is present in all four FGFR family members.Entities:
Year: 2017 PMID: 30108871 PMCID: PMC6072211 DOI: 10.1039/c7md00213k
Source DB: PubMed Journal: Medchemcomm ISSN: 2040-2503 Impact factor: 3.597